Seelos therapeutics to collaborate with the healey & amg center for als in an expanded access program funded by a grant from the national institute of neurological disorders and stroke under the accelerating access to critical therapies for als act (act for als)

- act for als funding is for an expanded access program to study sls-005 in amyotrophic lateral sclerosis patients who do not qualify for clinical trials new york , sept. 30, 2022 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will collaborate with the sean m.
SEEL Ratings Summary
SEEL Quant Ranking